价格

沙库巴曲缬沙坦 (Entresto)

Sacubitril/Valsartan

生产企业：Novartis

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

适应症

⑴用于在有慢性心力衰竭(NYHA类别II-IV)患者中减低对心力衰竭的心血管死亡及住院治疗慢性心力衰竭和射血分数降低。本品通常与其他心力衰竭治疗结合，代替一种ACE抑制药或其他血管紧张素II受体阻断药。 ⑵用于治疗原发性高血压.

品牌名

Entresto

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

SACUBITRIL-VALSARTAN DOSAGE REGIMEN FOR TREATING HEART FAILURE
EP 3294283 A1申请人: NOVARTIS AG优先权: 2015
EP
US
WO
6 件公开
NEW USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN
EP 4609912 A3申请人: NOVARTIS AG优先权: 2016
CN
EP
US
WO
5 件公开
SERIES OF HALOGENATED TETRACYCLIC TRITERPENE DERIVATIVES AND THEIR PREPARATION AND APPLICATION
US 2022177511 A1申请人: SHANGHAI KING X BIOTECH CO LTD优先权: 2019
CN
EP
US
WO
4 件公开
SACUBITRIL VALSARTAN SODIUM SUSTAINED-RELEASE COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF
US 2024307352 A1申请人: SHANGHAI AURORA BIOTECHNOLOGY CO LTD优先权: 2021
CN
EP
US
WO
4 件公开
AMORPHOUS TRISODIUM SACUBITRIL VALSARTAN AND PROCESS FOR ITS PREPARATION
EP 3532454 A4申请人: BIOCON LTD优先权: 2016
EP
US
3 件公开
丹酚酸B和/或三七总皂苷组合物及其应用
CN 117100733 B申请人: 广州白云山和记黄埔中药有限公司优先权: 2023
CN
3 件公开
SOLID STATE FORMS OF TRISODIUM VALSARTAN: SACUBITRIL
EP 3828175 A1申请人: TEVA PHARMACEUTICALS INT GMBH优先权: 2015
EP
US
2 件公开
COMBINATION FORMULATION COMPRISING SACUBITRIL-VALSARTAN AND SGLT-2 INHIBITOR HAVING IMPROVED STABILITY AND DISSOLUTION RATE
EP 4691459 A1申请人: HANMI PHARMACEUTICAL CO LTD优先权: 2023
EP
WO
2 件公开
A MULTILAYER TABLET COMPRISING SACUBITRIL AND VALSARTAN
EP 4780421 A1申请人: SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI优先权: 2023
EP
WO
2 件公开
A BILAYER TABLET COMPRISING SACUBITRIL AND VALSARTAN
EP 4780444 A1申请人: SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI优先权: 2023
EP
WO
2 件公开

药物